Jubilant Life Sciences Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Jubilant Life Sciences Ltd with respect to media flash on April 26, 2017 stating "Jubilant Life Said To Consider $500 m Singapore IPO Of Pharma Unit" and media report in The Financial Express on April 27, 2017 titled "Jubilant weighing Singapore IPO of Pharma unit" Jubilant Life Sciences Ltd response is enclosed. Clarification sought from Jubilant Life Sciences Ltd
The Exchange has sought clarification from Jubilant Life Sciences Ltd with respect to media flash on April 26, 2017 stating "Jubilant Life Said To Consider $500 m Singapore IPO Of Pharma Unit" and media report in The Financial Express on April 27, 2017 titled "Jubilant weighing Singapore IPO of Pharma unit"The reply is awaited. Updates
Disclosure under Regulation 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended
Jubilant Life gets USFDA nod for hypertension drug
Jubilant Life's product is the generic version of Benicar of Daiichi Sankyo, which is used for the treatment of hypertension Updates
We wish to inform you that in respect of Non-Convertible Debentures of the Company allotted on January 27, 2017, the Company has provided all the documents and intimations required to be submitted to the Debenture Trustees i.e. Vistra ITCL (India) Limited during the Financial Year 2016-17 in terms of the Trust Deed and the Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008. Certificate Under Regulation 40(9) And Regulation 40(10) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
As per Regulation 40 (9) and Regulation 40(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Certificate obtained from a Practising Company Secretary for the period ended March 31, 2017. Shareholding for the Period Ended March 31, 2017
Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here Jubilant Life Sciences raises Rs 100 cr
Jubilant Life Sciences has raised Rs 100 crore through issuance of commercial papers. The company had issued commercial papers worth Rs 100 crore on April 18, 2017. The tenure of the instrument is... 